Equities

Maat Pharma SA

Maat Pharma SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)9.40
  • Today's Change0.18 / 1.95%
  • Shares traded336.00
  • 1 Year change+4.44%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 15:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Maat Pharma SA is a France-based company, which is engaged into research and development in biotechnology sector. The Company specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

  • Revenue in EUR (TTM)2.23m
  • Net income in EUR-19.72m
  • Incorporated2014
  • Employees50.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Valbiotis SA4.73m-7.37m65.23m48.00--3.32--13.78-0.5904-0.59040.37981.240.15643.361.94---24.35-32.92-33.77-46.3648.7653.15-155.67-418.873.38-38.190.2598--502.93126.7340.16---21.71--
AFYREN SA3.38m-9.59m71.56m122.00--1.16--21.18-0.3696-0.36960.13032.370.0435--5.3927,696.72-12.35-9.58-13.42-10.4692.6395.57-283.69-162.61---1.620.0719---2.23---4.20------
AB Science SA777.00k-16.89m102.58m89.00------132.02-0.3561-0.35610.0164-0.38790.02840.3942.507,471.15-61.64-70.81-237.22-316.6388.1691.37-2,173.10-1,225.491.41--135.44---40.39-11.245.86--5.07--
Maat Pharma SA2.23m-19.72m109.19m50.00--5.34--49.01-1.73-1.730.1961.760.05084.844.1644,560.00-44.99-35.49-58.93-42.9874.28---884.96-1,157.542.76-49.610.4075--55.80---43.78--30.30--
Eurofins-Cerep SA46.17m9.21m109.96m233.0011.941.839.822.381,826.411,826.419,160.0011,939.290.68141.666.04220,892.0013.6015.1916.0618.9485.5767.3019.9519.725.17112.420.000050.0014.4514.3017.0924.52----
DBV Technologies SA4.88m-94.22m114.98m88.00--0.7503--23.55-1.00-1.000.05181.590.0209--0.373870,752.81-40.35-64.67-46.22-80.94--91.59-1,929.97-1,345.10----0.0128---15.14-18.452.08---38.41--
Adocia SA5.73m-20.55m121.96m100.00------21.30-2.36-2.360.6532-1.900.1823--16.7955,048.08-65.43-25.65-341.43-37.22-----358.85-101.110.5924-2.782.81--692.73-10.0869.67---40.08--
Transgene SA7.63m-22.33m125.46m158.00--8.01--16.43-0.2227-0.22270.07590.15530.1368--4.2848,316.46-40.00-24.81-50.27-29.79-----292.48-193.24----0.4764---23.681.5131.94--14.44--
Ose Immunotherapeutics SA2.23m-23.00m134.96m62.00--5.82--60.60-1.18-1.180.11661.060.0256--3.22---26.46-17.17-33.15-20.55-----1,032.87-94.71---97.810.6659---87.83-38.07-29.52---17.11--
Eurobio Scientific SA130.00m4.84m148.61m137.0033.610.9056.391.140.43150.431511.5916.020.40183.194.31948,927.001.4916.911.8021.5347.1150.953.7223.342.322.810.36660.00-14.8120.80-80.61--20.02--
Genfit SA38.18m-28.89m161.22m159.00--2.37--4.22-0.5814-0.58140.76811.360.1961542.003.52240,100.60-14.84-12.57-18.55-15.3094.3294.96-75.69-76.232.94-7.780.5080--43.7038.49-21.82---3.27--
Data as of May 03 2024. Currency figures normalised to Maat Pharma SA's reporting currency: Euro EUR

Institutional shareholders

0.19%Per cent of shares held by top holders
HolderShares% Held
Financi�re Arbevel SAas of 30 Dec 202220.00k0.17%
Gestys SAas of 26 Jan 20241.50k0.01%
Data from 23 Feb 2024 - 28 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.